IOL Chemicals and Pharmaceuticals Q4 FY25 results (Jan–Mar 2025) and concall

IOL Chemicals and Pharmaceuticals reported a resilient Q4 FY25 with revenue growing 4.7% YoY to INR528 crores and EBITDA increasing 17% to INR67 crores, driven by improved traction in Ibuprofen and enhanced efficiencies in chemical operations. Despite industry-wide pricing pressures in the pharmaceutical sector and lower-than-expected Paracetamol demand, the company successfully commissioned a fully backward integrated Paracetamol unit and acquired land for future expansion. The net debt to equity ratio remained low at 0.09, providing ample headroom for future growth.